Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Wednesday, 14 March 2018

Kiadis Pharma to Present at the Cowen and Company 38th Annual Health Care Conference

Kiadis Pharma N. V.    

Published: 08:06 CET 14-03-2018 /GlobeNewswire /Source: Kiadis Pharma N. V. / : KDS /ISIN: NL0011323407

Kiadis Pharma to Present at the Cowen and Company 38th Annual Health Care Conference

Kiadis Pharma to Present at the Cowen and Company 38th Annual Health Care Conference


Amsterdam, The Netherlands, March 14, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing a T-cell immunotherapy product designed to reduce Graft versus Host Disease (GVHD) in hematopoietic stem cell transplantations (HSCT), today announces that Arthur Lahr, Chief Executive Officer, will present at the Cowen 38th Annual Health Care Conference on Wednesday, March 14, 2018 at 10:00am EDT in Boston, MA.


The presentation will be webcast live and may be accessed by visiting:

http://wsw.com/webcast/cowen46/kds.as.  A replay of the webcast will be available for up to 90 days at www.kiadis.com


For more information, please contact:


Kiadis Pharma:

Karl Hård, Head of IR & Communications

Tel. +31 611 096 298


Optimum Strategic Communications:

Mary Clark, Supriya Mathur, Hollie Vile

Tel: +44 (0) 203 714 1787



About Kiadis Pharma

Kiadis Pharma's allodepleted T-cell immunotherapy product, given after a haploidentical hematopoietic stem cell transplantation (HSCT), is designed to reduce Graft versus Host Disease (GVHD). Single dose Phase 2 data with lead product ATIR101(TM) in patients with blood cancer shows a strong and clinically very relevant improvement over literature for the Baltimore protocol, with reduced risk of GVHD. Based on the positive results from the Phase 2 trial, the Company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in April 2017, for approval of ATIR101(TM) across the EU as an adjunctive treatment in HSCT for malignant disease. Kiadis Pharma received Day 120 questions in September 2017 and is on track for potential (conditional) approval in Q4 2018 and launch in H2 2019. Kiadis Pharma is conducting a Phase 3 trial with ATIR101(TM) across Europe and North America (head to head against the Baltimore protocol). The first patient was enrolled in December 2017.


In September 2017 the US Food and Drug Administration (FDA) granted ATIR101(TM) the Regenerative Medicine Advanced Therapy (RMAT) designation. ATIR101(TM) has been granted Orphan Drug Designations both in the US and Europe.


The Company's shares are listed on Euronext Amsterdam and Brussels under the ticker KDS.


Website: www.kiadis.com

Company presentation: http://www.kiadis.com/company-presentation/


Forward Looking Statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma's or, as appropriate, Kiadis Pharma's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis Pharma expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.


This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Kiadis Pharma N. V., Paasheuvelweg 25, Amsterdam-Zuidoost 1105 BP, The Netherlands
If you would like to unsubscribe and stop receiving these e-mails click here.